Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway
Stephen J. Harwood, Christopher R. Smith, J. David Lawson, John M. Ketcham
Abstract
Within the MAPK/RAS pathway, there exists a plethora of protein–protein interactions (PPIs). For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes to provide much needed therapies for patients with KRAS-mutant driven cancers. In this review, we focus on recent strategies to inhibit RAS-signaling via disrupting PPIs associated with SOS1, RAF, PDEδ, Grb2, and RAS.
Topics & Concepts
KRASMAPK/ERK pathwayEffectorGRB2Signal transductionAnti-apoptotic Ras signalling cascadeMutantCancer researchProtein–protein interactionComputational biologyCell biologyBiologyBioinformaticsChemistrySignal transducing adaptor proteinCancerGeneticsColorectal cancerGeneMelanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingMicrobial Natural Products and Biosynthesis